Why Opus Genetics (IRD) Stock Is Up Today

Opus Genetics (IRD) is up 35.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp move appears tied to new positive Phase 1/2 clinical data for OPGx-BEST1, the company’s gene therapy program for BEST1-related retinal diseases. Investors also seem encouraged that the program showed a clean safety profile, early signs of functional and structural benefit, and a clearer regulatory path after recent discussions with the FDA.

Details:

Opus Genetics announced positive 3- and 6-month results from the low-dose Cohort 1 of its BIRD-1 study on September 9, 2026.

The company said all five treated participants showed clinically meaningful improvement in visual function, while four of five also showed structural retinal improvements.

Management said there were no serious adverse events, no dose-limiting toxicities, and no intraocular inflammation observed in Cohort 1.

Opus Genetics also said the FDA aligned on a potential pivotal endpoint for a future trial, while Cohort 2 has already been over-enrolled and remains on track for additional topline data in 2027.

Sources:

Opus Genetics, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$IRD Insider Trading Activity

$IRD insiders have traded $IRD stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.

Here’s a breakdown of recent trading of $IRD stock by insiders over the last 6 months:

FIGHTING BLINDNESS RETINAL DEGENERATION FUND FOUNDATION sold 1,700,000 shares for an estimated $7,394,999
GEORGE MAGRATH (Chief Executive Officer) has made 0 purchases and 3 sales selling 43,424 shares for an estimated $204,899.
ROBERT E. GAGNON (Chief Financial Officer) has made 0 purchases and 3 sales selling 43,625 shares for an estimated $190,811.
BENJAMIN R YERXA (President) has made 0 purchases and 2 sales selling 14,899 shares for an estimated $61,185.
ASHWATH JAYAGOPAL (Chief Scientific & Dev. Ofc.) has made 0 purchases and 2 sales selling 11,261 shares for an estimated $58,201.
JOSEPH K SCHACHLE (Chief Operating Officer) has made 0 purchases and 3 sales selling 13,060 shares for an estimated $57,697.
RABOURN AMY ZAREMBA (Head of Fin. Quality Assurance) has made 0 purchases and 2 sales selling 4,457 shares for an estimated $23,309.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive IRD Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$IRD Hedge Fund Activity

We have seen 69 institutional investors add shares of $IRD stock to their portfolio, and 34 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

NANTAHALA CAPITAL MANAGEMENT, LLC removed 3,100,000 shares (-64.8%) from their portfolio in Q1 2026, for an estimated $14,105,000
BLACKROCK, INC. added 2,968,747 shares (+2009.4%) to their portfolio in Q2 2026, for an estimated $12,201,550
TRAILS EDGE CAPITAL PARTNERS, LP added 2,743,658 shares (+inf%) to their portfolio in Q2 2026, for an estimated $11,276,434
GREAT POINT PARTNERS LLC added 1,970,187 shares (+inf%) to their portfolio in Q2 2026, for an estimated $8,097,468
PERCEPTIVE ADVISORS LLC removed 1,835,842 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $7,545,310
GOLDMAN SACHS GROUP INC added 1,200,420 shares (+367.3%) to their portfolio in Q2 2026, for an estimated $4,933,726
SUMMITTX CAPITAL, L.P. added 1,007,351 shares (+inf%) to their portfolio in Q2 2026, for an estimated $4,140,212

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$IRD Price Targets

Multiple analysts have issued price targets for $IRD recently. We have seen 8 analysts offer price targets for $IRD in the last 6 months, with a median target of $11.5.

Here are some recent targets:

Thomas Shrader from BTIG set a target price of $12.0 on 07/06/2026
Andreas Argyrides from Chardan Capital set a target price of $13.0 on 07/06/2026
Matthew Caufield from HC Wainwright & Co. set a target price of $8.0 on 06/17/2026
Jonathan Wolleben from Citizens set a target price of $11.0 on 06/15/2026
Debjit Chattopadhyay from Guggenheim set a target price of $16.0 on 06/04/2026
Lili Nsongo from Leerink Partners set a target price of $10.0 on 05/21/2026
Steve Seedhouse from Cantor Fitzgerald set a target price of $15.0 on 03/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.